Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XNCR | US
0.18
1.04%
Healthcare
Biotechnology
30/06/2024
30/08/2024
17.49
17.43
17.71
17.09
Xencor Inc. a clinical stage biopharmaceutical company focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab a bispecific antibody which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab a bispecific antibody which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306 which is in Phase I clinical trial to treat solid tumors; XmAb104 which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509 which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434 which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease mild cognitive impairment and depression. It has a license agreement with Caris Life Sciences. Xencor Inc. was incorporated in 1997 and is headquartered in Monrovia California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
46.0%1 month
60.3%3 months
46.6%6 months
50.5%-
-
1.92
0.16
0.11
-17.27
4.94
-
-158.38M
1.08B
1.08B
-
-367.44
-
-62.70
-28.94
10.22
13.93
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.97
Range1M
5.94
Range3M
10.08
Rel. volume
0.82
Price X volume
5.95M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fluent Inc | COGT | Biotechnology | 10.74 | 1.18B | 4.47% | n/a | 4.87% |
AnaptysBio Inc | ANAB | Biotechnology | 38.09 | 1.15B | 4.01% | n/a | 3835.68% |
immatics biotechnologies GmbH | IMTX | Biotechnology | 11.09 | 1.14B | 0.09% | n/a | 0.00% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 16.52 | 1.13B | 1.35% | n/a | -216.56% |
Calliditas Therapeutics AB | CALT | Biotechnology | 40.12 | 1.08B | -0.99% | n/a | 944.17% |
Autolus Therapeutics Plc | AUTL | Biotechnology | 3.93 | 1.05B | 3.15% | n/a | 54.69% |
ELVN | ELVN | Biotechnology | 21.88 | 1.03B | -1.53% | n/a | 0.00% |
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 27.11 | 1.03B | -1.78% | n/a | 28.62% |
Array BioPharma Inc | ARRY | Biotechnology | 6.71 | 1.02B | -2.04% | 67.10 | 117.68% |
89bio Inc | ETNB | Biotechnology | 9.5 | 1.01B | 2.93% | n/a | 5.31% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.74 | 1.17B | -2.65% | n/a | 0.00% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 21.94 | 990.13M | 0.14% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 36.37 | 743.39M | 4.66% | n/a | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.25 | 722.36M | 0.32% | 56.82 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.94 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 49.80 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.70 | 0.00% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 28.64 | 316.93M | -0.52% | 18.84 | -621.78% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -17.27 | 0.97 | Cheaper |
Ent. to Revenue | 4.94 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 1.92 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 46.56 | 76.13 | Lower Risk |
Debt to Equity | 0.16 | -2.05 | Expensive |
Debt to Assets | 0.11 | 0.25 | Cheaper |
Market Cap | 1.08B | 4.04B | Emerging |